Debrisoquine: Difference between revisions
No edit summary |
m Protected "Debrisoquine": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
(No difference)
|
Latest revision as of 19:38, 18 August 2015
Names | |
---|---|
IUPAC name
1,2,3,4-tetrahydroisoquinoline-2-carboximidamide
| |
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChEMBL | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). |
KEGG | |
MeSH | Debrisoquine |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C10H13N3 | |
Molar mass | 175.23032 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
WikiDoc Resources for Debrisoquine |
Articles |
---|
Most recent articles on Debrisoquine Most cited articles on Debrisoquine |
Media |
Powerpoint slides on Debrisoquine |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Debrisoquine at Clinical Trials.gov Clinical Trials on Debrisoquine at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Debrisoquine
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Debrisoquine Discussion groups on Debrisoquine Patient Handouts on Debrisoquine Directions to Hospitals Treating Debrisoquine Risk calculators and risk factors for Debrisoquine
|
Healthcare Provider Resources |
Causes & Risk Factors for Debrisoquine |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug metabolizing enzyme.